• Je něco špatně v tomto záznamu ?

Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study

PC. Taylor, C. Ancuta, O. Nagy, MC. de la Vega, A. Gordeev, R. Janková, U. Kalyoncu, I. Lagunes-Galindo, J. Morović-Vergles, MPGUES. de Souza, B. Rojkovich, P. Sidiropoulos, A. Kawakami

. 2021 ; 15 (-) : 359-373. [pub] 20210217

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010455

Background: Patients' needs and perspectives are important determinants of treatment success in rheumatoid arthritis (RA). Assessing patients' perspectives can help identify unmet needs and enhance the understanding of treatment benefits. Objective: The SENSE study assessed the impact of inadequate response to disease-modifying antirheumatic drugs (DMARDs) on treatment satisfaction, disease outcomes, and patient perspectives related to RA disease management. Methods: SENSE was a noninterventional, cross-sectional study conducted in 18 countries across Europe, Asia, and South America. Adult patients with poorly controlled RA of moderate/high disease activity were eligible. Patient satisfaction was assessed by the Treatment Satisfaction Questionnaire for Medication (TSQM v1.4). Treatment adherence, healthcare resource utilization (HRU), quality of life (QoL), work ability, digital health literacy (DHL), patient preference information, and treatment strategy were also assessed. Results: A total of 1624 patients were included in the study: most were female (84.2%) and middle-aged, and mean disease duration was 10.5 years. Mean TSQM global satisfaction subscore was 60.9, with only 13.5% of patients reporting good treatment satisfaction (TSQM global ≥80). The strongest predictor of good treatment satisfaction was treatment with advanced therapies. Most patients (87.4%) reported good treatment adherence. In general, patients had impaired QoL and work ability, high HRU, and 67.4% had poor DHL. Leading treatment expectations were "general improvement of arthritis" and "less joint pain". Most patients preferred oral RA medications (60.7%) and rapid (≤1 week) onset of action (71.1%). "Increased risk for malignancies" and "increased risk for cardiovascular disease" were the least acceptable side effects. Despite suboptimal control, advanced therapies were only used in a minority of patients, and DMARD switches were planned for only half of the patients. Conclusion: Suboptimal disease control negatively impacts treatment satisfaction, work ability, QoL, and HRU. Data collected on patient perspectives may inform shared decision-making and optimize treat-to-target strategies for improving patient outcomes in RA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010455
003      
CZ-PrNML
005      
20210610101413.0
007      
ta
008      
210413s2021 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/PPA.S289692 $2 doi
035    __
$a (PubMed)33633444
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Taylor, Peter C $u Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
245    10
$a Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study / $c PC. Taylor, C. Ancuta, O. Nagy, MC. de la Vega, A. Gordeev, R. Janková, U. Kalyoncu, I. Lagunes-Galindo, J. Morović-Vergles, MPGUES. de Souza, B. Rojkovich, P. Sidiropoulos, A. Kawakami
520    9_
$a Background: Patients' needs and perspectives are important determinants of treatment success in rheumatoid arthritis (RA). Assessing patients' perspectives can help identify unmet needs and enhance the understanding of treatment benefits. Objective: The SENSE study assessed the impact of inadequate response to disease-modifying antirheumatic drugs (DMARDs) on treatment satisfaction, disease outcomes, and patient perspectives related to RA disease management. Methods: SENSE was a noninterventional, cross-sectional study conducted in 18 countries across Europe, Asia, and South America. Adult patients with poorly controlled RA of moderate/high disease activity were eligible. Patient satisfaction was assessed by the Treatment Satisfaction Questionnaire for Medication (TSQM v1.4). Treatment adherence, healthcare resource utilization (HRU), quality of life (QoL), work ability, digital health literacy (DHL), patient preference information, and treatment strategy were also assessed. Results: A total of 1624 patients were included in the study: most were female (84.2%) and middle-aged, and mean disease duration was 10.5 years. Mean TSQM global satisfaction subscore was 60.9, with only 13.5% of patients reporting good treatment satisfaction (TSQM global ≥80). The strongest predictor of good treatment satisfaction was treatment with advanced therapies. Most patients (87.4%) reported good treatment adherence. In general, patients had impaired QoL and work ability, high HRU, and 67.4% had poor DHL. Leading treatment expectations were "general improvement of arthritis" and "less joint pain". Most patients preferred oral RA medications (60.7%) and rapid (≤1 week) onset of action (71.1%). "Increased risk for malignancies" and "increased risk for cardiovascular disease" were the least acceptable side effects. Despite suboptimal control, advanced therapies were only used in a minority of patients, and DMARD switches were planned for only half of the patients. Conclusion: Suboptimal disease control negatively impacts treatment satisfaction, work ability, QoL, and HRU. Data collected on patient perspectives may inform shared decision-making and optimize treat-to-target strategies for improving patient outcomes in RA.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ancuta, Codrina $u Department of Rheumatology, "Grigore T. Popa" University of Medicine and Pharmacy, Iași, Romania
700    1_
$a Nagy, Orsolya $u AbbVie Inc, North Chicago, IL, USA
700    1_
$a de la Vega, María C $u CEIM Investigaciones Medicas, Buenos Aires, Argentina
700    1_
$a Gordeev, Andrey $u V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation
700    1_
$a Janková, Radka $u Department of Pediatric and Adult Rheumatology, Faculty Hospital Motol, Prague, Czech Republic
700    1_
$a Kalyoncu, Umut $u Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey
700    1_
$a Lagunes-Galindo, Ivan $u AbbVie Inc, North Chicago, IL, USA
700    1_
$a Morović-Vergles, Jadranka $u Department of Internal Medicine, Division of Clinical Immunology, Allergology and Rheumatology, Dubrava University Hospital, University of Zagreb School of Medicine, Zagreb, Croatia
700    1_
$a de Souza, Mariana Peixoto G U E Silva $u Santa Casa de Belo Horizonte, Belo Horizonte, Brazil
700    1_
$a Rojkovich, Bernadette $u Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, Hungary
700    1_
$a Sidiropoulos, Prodromos $u Faculty of Medicine, University of Crete, Heraklion, Greece
700    1_
$a Kawakami, Atsushi $u Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
773    0_
$w MED00165877 $t Patient preference and adherence $x 1177-889X $g Roč. 15, č. - (2021), s. 359-373
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33633444 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210610101412 $b ABA008
999    __
$a ind $b bmc $g 1649813 $s 1130831
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 15 $c - $d 359-373 $e 20210217 $i 1177-889X $m Patient preference and adherence $n Patient prefer. adherence $x MED00165877
LZP    __
$a Pubmed-20210413

Najít záznam

Citační ukazatele

Možnosti archivace